Nelfinavir Mesylate: A Protease Inhibitor

OBJECTIVE: To review the clinical pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of nelfinavir mesylate. DATA SOURCE: A MEDLINE search restricted to English-language literature from January 1966 to February 1998 and an extensive review of journals...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Pharmacotherapy 1999-03, Vol.33 (3), p.325-339
Main Authors: Pai, Vinita B, Nahata, Milap C
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Child
Child, Preschool
Clinical Trials as Topic
Drug Interactions
HIV Infections - drug therapy
HIV Protease Inhibitors - pharmacology
HIV Protease Inhibitors - therapeutic use
Humans
Medical sciences
Nelfinavir - pharmacology
Nelfinavir - therapeutic use
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: To review the clinical pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage guidelines of nelfinavir mesylate. DATA SOURCE: A MEDLINE search restricted to English-language literature from January 1966 to February 1998 and an extensive review of journals was conducted to prepare this article. MeSH headings included protease inhibitors, nelfinavir mesylate, and AG1343. Abstracts presented at meetings and data submitted to the Food and Drug Administration (FDA) were also reviewed. DATA EXTRACTION: The data on efficacy, pharmacokinetics, adverse effects, and drug interactions were obtained from in vitro studies, as well as open-label and controlled trials. DATA SYNTHESIS: Nelfinavir inhibits HIV protease enzyme resulting in formation of immature and noninfectious virions. In combination with nucleoside reverse transcriptase inhibitors, nelfinavir is effective in reducing the viral load below the quantifiable limit (
ISSN:1060-0280
1542-6270
DOI:10.1345/aph.18089